Protalix BioTherapeutics (PLX) EBITDA Margin Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 2,002.00 |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -3,558.00 |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 29,091.00 |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | -1,651.00 |
| 10 | Protalix BioTherapeutics | 189.57 Mn | 148.91 Mn | 12.13 Mn | 1,591.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,600.00 |
| Mar 31, 2026 | 10,364.00 |
| Dec 31, 2025 | -9,063.00 |
| Sep 30, 2025 | -1,029.00 |
| Jun 30, 2025 | 2,550.00 |
| Mar 31, 2025 | 8,858.00 |
| Dec 31, 2024 | 9,312.00 |
| Sep 30, 2024 | 4,046.00 |
| Jun 30, 2024 | -7,623.00 |
| Mar 31, 2024 | -10,392.00 |
| Dec 31, 2023 | -2,459.00 |
| Sep 30, 2023 | 379.00 |
| Jun 30, 2023 | 12,133.00 |
| Mar 31, 2023 | -1,402.00 |
| Dec 31, 2022 | 3,779.00 |
| Sep 30, 2022 | -640.00 |
| Jun 30, 2022 | 7,951.00 |
| Mar 31, 2022 | 2,110.00 |
| Dec 31, 2021 | -8,131.00 |
| Sep 30, 2021 | 829.00 |